Barrett's oESophagus trial 3 (BEST3): study protocol for a randomised controlled trial comparing the Cytosponge-TFF3 test with usual care to facilitate the diagnosis of oesophageal pre-cancer in primary care patients with chronic acid reflux

Autor: Offman, J, Muldrew, B, O'Donovan, M, Debiram-Beecham, I, Pesola, F, Kaimi, I, Smith, SG, Wilson, A, Khan, Z, Lao-Sirieix, P, Aigret, B, Walter, FM, Rubin, G, Morris, S, Jackson, C, Sasieni, P, Fitzgerald, RC, BEST3 Trial team

Publikováno v: BMC Cancer, Vol 18, Iss 1, Pp 1-16 (2018)

Background: Early detection of oesophageal cancer improves outcomes; however, the optimal strategy for identifying patients at increased risk from the pre-cancerous lesion Barrett’s oesophagus (BE) is not clear. The Cytosponge, a novel non-endoscop

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f2ba16987a53a862d49fd59774ca778

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Barrett's oESophagus trial 3 (BEST3): study protocol for a randomised controlled trial comparing the Cytosponge-TFF3 test with usual care to facilitate the diagnosis of oesophageal pre-cancer in primary care patients with chronic acid reflux.

Autor: Offman J; School of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences & Medicine, King's College London, London, UK., Muldrew B; Cancer Prevention Trials Unit, Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, UK., O'Donovan M; Department of Histopathology, Addenbrooke's Hospital, Cambridge, UK., Debiram-Beecham I; MRC Cancer Unit, Hutchison/MRC Research Centre, University of Cambridge, Cambridge, UK., Pesola F; School of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences & Medicine, King's College London, London, UK., Kaimi I; Cancer Prevention Trials Unit, Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, UK., Smith SG; Leeds Institute of Health Sciences, University of Leeds, Leeds, UK., Wilson A; Cancer Prevention Trials Unit, Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, UK., Khan Z; Cancer Prevention Trials Unit, Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, UK., Lao-Sirieix P; Astra Zeneca, Cambridge, UK., Aigret B; Cancer Prevention Trials Unit, Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, UK., Walter FM; The Primary Care Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK., Rubin G; Institute of Health and Society, Sir James Spence Institute, Royal Victoria Infirmary, Newcastle University, Newcastle upon Tyne, UK., Morris S; Department of Applied Health Research, University College London, London, UK., Jackson C; MRC Biostatistic Unit, University of Cambridge, Cambridge, UK., Sasieni P; School of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences & Medicine, King's College London, London, UK.; Cancer Prevention Trials Unit, Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, UK., Fitzgerald RC; MRC Cancer Unit, Hutchison/MRC Research Centre, University of Cambridge, Cambridge, UK. RCF29@MRC-CU.cam.ac.uk.

Publikováno v: BMC cancer [BMC Cancer] 2018 Aug 03; Vol. 18 (1), pp. 784. Date of Electronic Publication: 2018 Aug 03.